<DOC>
	<DOCNO>NCT00628745</DOCNO>
	<brief_summary>THAOS global , multi-center , longitudinal observational survey open patient transthyretin-associated amyloidoses ( ATTR ) , include ATTR-PN ( polyneuropathy ) , ATTR-CM ( cardiomyopathy ) wild-type ATTR-CM . It open-ended minimum duration 10 year . Patients follow long able participate . The principal aim outcome survey well understand characterize natural history disease study large heterogenous patient population . Survey data may use develop new treatment guideline recommendation , inform educate clinician management disease .</brief_summary>
	<brief_title>Transthyretin-Associated Amyloidoses Outcome Survey ( THAOS )</brief_title>
	<detailed_description>n/a NA</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Amyloid Neuropathies , Familial</mesh_term>
	<criteria>Patients must meet follow inclusion criterion eligible enrollment THAOS : 1 . Evidence personally sign date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect study . 2 . Males females 18 year age . 3 . Confirmed genotyped TTR mutation without diagnosis ATTR , wildtype TTR amyloidosis . Confirmation wildtype TTR amyloidosis determine genotyped confirmation patient posse know mutation TTR gene ( ie , carrier wildtype allele ) via genetic test one follow set criterion ( A , B , C ) : 1 . Evidence cardiac involvement echocardiogram define mean left ventricle wall thickness &gt; 12 mm , presence amyloid cardiac biopsy tissue confirm TTR amyloid mass spectrometry immunohistochemistry ; 2 . Evidence cardiac involvement echocardiogram define mean left ventricle wall thickness &gt; 12 mm , presence amyloid noncardiac tissue confirm TTR amyloid mass spectrometry immunohistochemistry ; 3 . Evidence cardiac involvement echocardiogram define mean left ventricle wall thickness &gt; 12 mm , evidence primary ( light chain ) amyloidosis , presence amyloid cardiac tissue indirectly confirm scintigraphy `` bone seek tracer '' eg , 99mTCDPD [ 99mTC3,3diphosphono1,2propanodicarboxylic acid ] , 99mTC PYP [ Pyrophosphate ] , 99mTCHMDP [ hydroxymethylene diphosphonate ] Perugini grade great equal 2 . Exclusion Criteria Patients present follow included THAOS : 1 . Patient primary secondary amyloidosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>TRANSTHYRETIN</keyword>
	<keyword>AMYLOIDOSIS</keyword>
	<keyword>TRANSTHYRETIN AMYLOIDOSIS</keyword>
</DOC>